Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EBT (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of EBT readings, the most recent being $2.1 million for Q4 2025.

  • On a quarterly basis, EBT rose 242.11% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.8 million, a 1651.93% decrease, with the full-year FY2025 number at -$9.6 million, down 179.92% from a year prior.
  • EBT hit $2.1 million in Q4 2025 for Fennec Pharmaceuticals, up from -$623000.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $12.9 million in Q1 2024 to a low of -$8.0 million in Q3 2022.
  • Median EBT over the past 5 years was -$3.9 million (2021), compared with a mean of -$2.9 million.
  • The widest YoY moves for EBT: up 316.58% in 2024, down 222.47% in 2024.
  • Fennec Pharmaceuticals' EBT stood at -$4.2 million in 2021, then crashed by 63.58% to -$6.9 million in 2022, then soared by 62.03% to -$2.6 million in 2023, then skyrocketed by 42.67% to -$1.5 million in 2024, then surged by 242.11% to $2.1 million in 2025.
  • The last three reported values for EBT were $2.1 million (Q4 2025), -$623000.0 (Q3 2025), and -$3.2 million (Q2 2025) per Business Quant data.